MyRisk is the first hereditary cancer test to ... President and Chief Clinical Officer of Oncology, Myriad Genetics. “By making germline testing interoperable with OncoEMR, we aim to simplify ...

In October 2024, Myriad Genetics entered a collaboration with Flatiron Health, a leading health technology company, that ...

盐湖城 - 专门从事基因测试和精准医疗的Myriad Genetics, Inc. (NASDAQ: MYGN)宣布对联合健康最近的政策更新表示不同意。该保险公司计划从2025年1月1日起，在其商业和个人交换福利计划下限制多基因组药物基因组学测试的覆盖范围，包括Myriad的GeneSight测试。 这一政策变更于周五传达给Myriad，公司对此表示惊讶和失望。Myriad的总裁兼首席执行官Pau ...

SALT LAKE CITY - Myriad Genetics , Inc. (NASDAQ: NASDAQ:MYGN) announced today a collaboration with Flatiron Health to integrate its MyRisk Hereditary Cancer Test into Flatiron's OncoEMR platform. This ...

Myriad’s MyRisk ® test is the first hereditary cancer test integrated into Flatiron’s OncoEMR ® SALT LAKE CITY, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a ...

This month, Myriad Genetics partnered with Flatiron Health to integrate Myriad’s MyRisk Hereditary Cancer Test into ...

(NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a collaboration with Flatiron Health, a leading health tech company dedicated to expanding the possibilities of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Haemophilia A is caused by variants in the gene that encodes coagulation factor VIII (FVIII). Sequencing of this gene in the 1980s was the initial step in developing replacement therapy with ...

Nov. 4, 2024 — Researchers used genomics to investigate the genetic changes causing resistance to transgenic crops in field populations of the corn earworm, also ...